1313P Patient-reported outcomes (PROs) in the LUMINOSITY trial: Evaluating telisotuzumab vedotin (Teliso-V) in patients (Pts) with c-Met protein overexpressing (OE), EGFR wildtype, non-squamous non-small cell lung cancer (NSQ NSCLC)
作者
Nicolas Girard,S. Lu,Jair Bar,Qingqing Xu,S. Ng,Rohini Sen,Z. Majd,Irene Nsiah,C. Ratajczak,M.S. Xia,Sudeep J Karve,D. Ross Camidge